Cristiano Amarelli

Dr. Cristiano Amarelli

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MCMaurizio Cotrufo
Maurizio Cotrufo
Alessandro Della CorteAlessandro Della Corte
Alessandro Della Corte
LSLuca S. De Santo
Luca S. De Santo
CQCesare Quarto
Cesare Quarto
MFMarisa De Feo
Marisa De Feo
SMStefania Montagnani
Stefania Montagnani

6 February 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
ABAlexander M. Bernhardt
Alexander M. Bernhardt
HCHannah Copeland
Hannah Copeland
ADAnita Deswal
Anita Deswal
JGJason Gluck
Jason Gluck
MGMichael M. Givertz
Michael M. Givertz
TNTien M.H. Ng
Tien M.H. Ng

1 July 2010 in American Heart Journal
Verified
Journal Article
Closed access
MTMichele Torella
Michele Torella
DTDaniele Torella
Daniele Torella
PCPaolo Chiodini
Paolo Chiodini
MFMarco Franciulli
Marco Franciulli
GRGiampaolo Romano
Giampaolo Romano
GNGianantonio Nappi
Gianantonio Nappi

1 February 2022 in Metabolism
Verified
Journal Article
Open access
Raffaele MarfellaRaffaele Marfella
Raffaele Marfella
NDNunzia D'Onofrio
Nunzia D'Onofrio
MTMaria Consiglia Trotta
Maria Consiglia Trotta
CSCelestino Sardu
Celestino Sardu
LSLucia Scisciola
Lucia Scisciola
GPGiuseppe Paolisso
Giuseppe Paolisso
The pathogenesis of experimental diabetic cardiomyopathy may involve the activator protein 1 (AP-1) member, JunD. Using non-diabetic heart transplant (HTX) in recipients with diabetes, we examined the effects of the diabetic milieu (hyperglycemia and insulin resistance) on cardiac JunD expression over 12 months. Because sodium/glucose cotransporter-2 inhibitors (SGLT2i) significantly reverse high glucose-induced AP-1 binding in the proximal tubular cell, we investigated JunD expression in a subgroup of type 2 diabetic recipients receiving SGLT2i treatment. We evaluated 77 first HTX recipients (40 and 37 patients with and without diabetes, respectively). Among the recipients with diabetes, 17 (45.9%) were receiving SGLT2i treatment. HTX recipients underwent standard clinical evaluation (metabolic status, echocardiography, coronary computed tomography angiography, and endomyocardial biopsy). In the biopsy samples, we evaluated JunD, insulin receptor substrates 1 and 2 (IRS1 and IRS2), peroxisome proliferator-activated receptor-γ (PPAR-γ), and ceramide levels using real-time polymerase chain reaction and immunofluorescence. The biopsy evaluations in this study were performed at 1-4 weeks (basal), 5-12 weeks (intermediate), and up to 48 weeks (final, end of 12-month follow-up) after HTX. There was a significant early and progressive increase in the cardiac expression of JunD/PPAR-γ and ceramide levels, along with a significant decrease in IRS1 and IRS2 in recipients with diabetes but not in those without diabetes. These molecular changes were blunted in patients with diabetes receiving SGLT2i treatment. Early pathogenesis in human diabetic cardiomyopathy is associated with JunD/PPAR-γ overexpression and lipid accumulation following HTX in recipients with diabetes. Remarkably, this phenomenon was reduced by concomitant therapy with SGLT2i, which acted directly on diabetic hearts.

1 March 2020 in JACC
Verified
Journal Article
Open access
Raffaele MarfellaRaffaele Marfella
Raffaele Marfella
Cristiano AmarelliCristiano Amarelli
Cristiano Amarelli
FCFrancesco Cacciatore
Francesco Cacciatore
Maria  Luisa BalestrieriMaria Luisa Balestrieri
Maria Luisa Balestrieri
Gelsomina MansuetoGelsomina Mansueto
Gelsomina Mansueto
CNClaudio Napoli
Claudio Napoli
Early pathogenesis of diabetic cardiomyopathy (DMCM) may involve lipotoxicity of cardiomyocytes in the context of hyperglycemia. There are many preclinical studies of DMCM pathogenesis, but the human evidence is still poorly understood. By using a nondiabetic mellitus (non-DM) heart transplanted (HTX) in diabetes mellitus (DM) recipients, this study conducted a serial study of human heart transplant recipients evaluating cardiac effects of diabetic milieu (hyperglycemia and insulin resistance) on lipotoxic-mediated injury. We evaluated cardiomyocyte morpho-pathology by seriated biopsies of healthy implanted hearts in DM recipients during 12-month follow-up from HTX. Because metformin reduces ectopic lipid accumulation, we evaluated the effects of the drug in a nonrandomized subgroup. The DMCM-AHEAD (Diabetes and Lipid Accumulation and Heart Transplant) prospective ongoing study (NCT03546062) evaluated 158 first HTX recipients (82 non-DM, 76 DM of whom 35 [46%] were receiving metformin). HTX recipients were undergoing clinical standard evaluation (metabolic status, echocardiography, coronary computed tomography angiography, and endomyocardial biopsies). Biopsies evaluated immune response, Oil Red-O staining, ceramide, and triacylglycerol levels. Lipotoxic factors and insulin resistance were evaluated by reverse transcriptase-polymerase chain reaction. There was a significant early and progressive cardiomyocyte lipid accumulation in DM but not in non-DM recipients (p = 0.019). In the subgroup receiving metformin, independently from immunosuppressive therapy that was similar among groups, lipid accumulation was reduced in comparison with DM recipients not receiving the drug (hazard ratio: 6.597; 95% confidence interval: 2.516 to 17.296; p < 0.001). Accordingly, lipotoxic factors were increased in DM versus non-DM recipients, and, relevantly, metformin use was associated with fewer lipotoxic factors. Early pathogenesis of human DMCM started with cardiomyocyte lipid accumulation following HTX in DM recipients. Metformin use was associated with reduced lipid accumulation independently of immunosuppressive therapy. This may constitute a novel target for therapy of DMCM.

6 February 2023 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
ABAlexander M. Bernhardt
Alexander M. Bernhardt
HCHannah Copeland
Hannah Copeland
ADAnita Deswal
Anita Deswal
JGJason Gluck
Jason Gluck
MGMichael M. Givertz
Michael M. Givertz
KKKay Kendall
Kay Kendall